Ocugen Q2 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said the company’s modified gene therapy platform is designed to address complex retinal diseases by modulating nuclear hormone receptors that regulate multiple gene networks, rather than targeting individual mutations. The company is advancing the platform in retinitis pigmentosa, Stargardt disease and geographic atrophy.
Musunuri said the three diseases represent a combined patient population of about 3 million people across the U.S. and Europe. Across its pipeline, including expanded-access-program patients, Ocugen has treated more than 325 patients across multiple doses and indications without observing a drug-related serious adverse event, he said.
The company said it remains on track to file three biologics license applications, or BLAs, by 2028. Ocugen expects top-line data for OCU400 and OCU410ST during the first half of 2027.
OCU410 Phase III Trial Planned for September
Ocugen received FDA clearance to initiate its ArMaDa-3 Phase III registrational trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The company plans to begin the global trial by September 2026.
The study is expected to enroll about 237 participants and use a 2:1 randomization between the OCU410 treatment arm and control arm. Chief Medical Officer Mohammed Genead said participants will be followed for 12 months, with the study evaluating a primary efficacy endpoint as well as key functional endpoints.
Genead said the sample size and 95% statistical power were based on results from the prior ArMaDa-1 Phase I/II trial and were discussed with the FDA. The prior trial showed a statistically significant 31% reduction in geographic atrophy lesion growth at the selected dose among patients with lesion sizes between 2.5 and 17.5 square millimeters, according to Musunuri. The company also reported 27% preservation of the ellipsoid zone in that population.
Ocugen is targeting BLA and market authorization application filings for OCU410 in 2028. Musunuri said the company views geographic atrophy as its largest commercial opportunity, estimating a U.S. and European patient population of roughly 2 million to 3 million people.
Stargardt and Retinitis Pigmentosa Programs Advance
For OCU410ST in Stargardt disease, Ocugen completed enrollment and dosing in the Phase II/III GUARDIAN3 pivotal confirmatory trial, which enrolled 63 participants. The company expects an interim outcome decision involving the first half of enrolled subjects during the third quarter of 2026 and top-line data in the second quarter of 2027. A BLA submission is planned for mid-2027.
Genead said the GUARDIAN3 study includes patients age 3 and older, a broad range of disease stages and lesion sizes, and variants associated with ABCA4-related retinopathy. The primary endpoint is lesion-based because the trial has a one-year duration, Musunuri said, while visual-function measures are being monitored as secondary endpoints.
In discussing earlier data, Genead said the company observed slowing of structural progression and functional benefits in its Phase I study. He said some patients demonstrated improvement in visual function, including a six-letter gain, or nearly one line, between treated and untreated eyes.
Meanwhile, enrollment has been completed in the Phase III liMeliGhT trial of OCU400 for retinitis pigmentosa. The trial enrolled 140 patients randomized 2:1 between treatment and control across RHO and gene-agnostic arms, encompassing more than 30 genetic mutations and patients from pediatric through later-stage disease populations.
Top-line data from liMeliGhT are expected in the first quarter of 2027. Ocugen said it could potentially receive approval for OCU400 in the fourth quarter of 2027, contingent on the expected regulatory process.
The primary endpoint in the trial is a 12-month change in visual function measured through luminance dependent navigation assessment. Musunuri said process performance qualification batches have been completed to support the BLA and commercial supply.
International and Commercial Planning
In July, Ocugen signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400 in retinitis pigmentosa across the Middle East and North Africa.
Musunuri said the company has alignment from both the FDA and European Medicines Agency that the U.S. OCU400 trial could support approvals. He added that regulatory pathways in MENA and other regions are expected to be linked to U.S. FDA approval.
Ocugen said it is also pursuing other regional commercialization partnerships. Its commercial preparations include discussions with CMS and payers, identifying specialized treatment centers capable of subretinal procedures, assessing manufacturing and distribution needs, and building marketing and sales capabilities.
Quarterly Expenses Rise; Cash Runway Extended Into 2028
Chief Financial Officer Rita Johnson-Greene reported total operating expenses of $17.9 million in the second quarter, compared with $15.2 million in the prior-year quarter. Research and development expense rose to $10.7 million from $8.4 million, while general and administrative expense increased to $7.2 million from $6.8 million.
For the first six months of 2026, operating expenses totaled $37.3 million, compared with $31.2 million a year earlier. Ocugen reported a net loss of $0.07 per common share for the second quarter, compared with a loss of $0.05 per share in the year-earlier period.
Following a $130 million convertible notes financing, Ocugen had $100.4 million in cash equivalents and restricted cash as of June 30. Johnson-Greene said the financing extended the company’s cash runway into 2028 and supports execution of its late-stage clinical programs.
She also cited potential additional funding sources, including a priority review voucher tied to OCU410ST’s rare pediatric disease designation, potential regional business-development agreements, Janus Henderson warrants that could provide $15 million if exercised, and potential equity financing. Ocugen expects to hold a special meeting in September to seek an increase in authorized shares.
About Ocugen (NASDAQ:OCGN)
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Source MarketBeat
